Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP3K7 | O43318 | 3/20 | 0.37 |
| ▸ | TAB1 | Q15750 | 3/20 | 0.37 |
| ▸ | DGAT1 | O75907 | 3/20 | 0.37 |
| ▸ | ADK | P55263 | 2/20 | 0.34 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21678534 | 0.90 | MAP3K7 (0.35) | MAP3K7TAB1DGAT1ADK | |
| SCHEMBL13494123 | 0.88 | RPS6KA3 (0.43) | MAP3K7TAB1RPS6KA3 | |
| SCHEMBL21678406 | 0.83 | DGAT1 (0.33) | DGAT1ADK | |
| SCHEMBL21678412 | 0.81 | DGAT1 (0.32) | DGAT1ADK | |
| SCHEMBL21801389 | 0.80 | DGAT1 (0.32) | DGAT1ADK | |
| SCHEMBL21801390 | 0.80 | DGAT1 (0.32) | DGAT1ADK | |
| SCHEMBL16259168 | 0.76 | ADK (0.40) | DGAT1ADK | |
| SCHEMBL31340598 | 0.76 | ADK (0.40) | DGAT1ADK | |
| SCHEMBL25282686 | 0.75 | ADK (0.42) | DGAT1ADK | |
| SCHEMBL16785958 | 0.75 | DGAT1 (0.36) | DGAT1ADK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260035373-A1 | PYRROLOPYRIMIDINE ITK INHIBITORS | ACLARIS THERAPEUTICS INC (US) | 2026-02-05 | — | — | US | disclosed |
| US-12297203-B2 | Pyrrolopyrimidine ITK inhibitors | ACLARIS THERAPEUTICS, INC. (US) | 2025-05-13 | — | — | US | disclosed |
| US-11820775-B2 | Pyrrolopyrimidine ITK inhibitors | ACLARIS THERAPEUTICS, INC. (US) | 2023-11-21 | — | — | US | disclosed |
| US-11820775-B2 | Pyrrolopyrimidine ITK inhibitors | ACLARIS THERAPEUTICS, INC. (US) | 2023-11-21 | — | — | US | disclosed |
| US-11820775-B2 | Pyrrolopyrimidine ITK inhibitors | ACLARIS THERAPEUTICS, INC. (US) | 2023-11-21 | — | — | US | disclosed |
| US-20220348579-A1 | PYRROLOPYRIMIDINE ITK INHIBITORS | ACLARIS THERAPEUTICS, INC. | 2022-11-03 | — | — | US | disclosed |
| US-11021482-B2 | Pyrrolopyrimidine ITK inhibitors | Adaris Therapeutics, Inc. (US) | 2021-06-01 | — | — | US | disclosed |
| US-20200048262-A1 | PYRROLOPYRIMIDINE ITK INHIBITORS | ACLARIS THERAPEUTICS, INC. | 2020-02-13 | — | — | US | disclosed |
| WO-2020033955-A1 | PYRROLOPYRIMIDINE ITK INHIBITORS | ACLARIS THERAPEUTICS, INC. (US) | 2020-02-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260035373-A1 | PYRROLOPYRIMIDINE ITK INHIBITORS | JAK3, JAK1, JAK2 | MAP3K7 206/4885TAB1 283/4885DGAT1 4560/4885 |
| US-20200048262-A1 | PYRROLOPYRIMIDINE ITK INHIBITORS | ITK, PDXK, DMPK | MAP3K7 148/4885TAB1 612/4885DGAT1 4090/4885 |
| US-12297203-B2 | Pyrrolopyrimidine ITK inhibitors | ITK, PDXK, DMPK | MAP3K7 148/4885TAB1 612/4885DGAT1 4090/4885 |
| US-20220348579-A1 | PYRROLOPYRIMIDINE ITK INHIBITORS | ITK, PDXK, DMPK | MAP3K7 148/4885TAB1 612/4885DGAT1 4090/4885 |
| US-11021482-B2 | Pyrrolopyrimidine ITK inhibitors | ITK, PDXK, DMPK | MAP3K7 148/4885TAB1 612/4885DGAT1 4090/4885 |
| US-11820775-B2 | Pyrrolopyrimidine ITK inhibitors | ITK, PDXK, DMPK | MAP3K7 148/4885TAB1 612/4885DGAT1 4090/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.